Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 4/20 | 0.78 |
| ▸ | RAB9A | P51151 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | HPGD | P15428 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.78 |
| ▸ | TRPM2 | O94759 | 4/20 | 0.77 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.77 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.77 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MMP1 | P03956 | 3/20 | 0.62 |
| ▸ | MMP2 | P08253 | 3/20 | 0.62 |
| ▸ | MMP9 | P14780 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779999 | 1.00 | TRPA1 (1.00) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL294402 | 0.90 | TRPM2 (0.83) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL294403 | 0.90 | TRPM2 (0.83) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2778920 | 0.88 | TRPM2 (0.81) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2778922 | 0.88 | TRPM2 (0.81) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29401064 | 0.88 | TRPM2 (0.81) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8638857 | 0.87 | SMN1; SMN2 (1.00) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL8638865 | 0.87 | SMN1; SMN2 (1.00) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28809046 | 0.87 | TRPM2 (1.00) | TRPA1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28809051 | 0.87 | TRPM2 (1.00) | TRPA1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | claimed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | claimed |
| WO-2010071865-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2173167-A2 | TREATMENT OF NEUROPATHIC PAIN | Nuon Therapeutics, Inc. (US) | 2010-04-14 | — | — | EP | claimed |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) | 2010-02-18 | — | — | US | claimed |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM | 2009-12-17 | — | — | US | claimed |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | NUON THERAPEUTICS, INC. | 2009-08-06 | — | — | US | claimed |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS INC. | 2009-02-12 | — | — | US | claimed |
| WO-2009008997-A2 | TREATMENT OF NEUROPATHIC PAIN | NUON THERAPEUTICS, INC. (US) | 2009-01-15 | — | — | WO | claimed |
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | EBERHARD-KARLS-UNIVERSITAT TUBINGEN (DE) | 2008-05-01 | — | — | US | claimed |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | ANGIOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2008-01-10 | — | — | US | claimed |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | LI, YINGJI (CN) | 2014-03-13 | — | — | US | disclosed |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | GRAND VALLEY STATE UNIVERSITY | 2011-03-03 | — | — | US | disclosed |
| EP-2253313-A1 | Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2010071866-A2 | COMBINATION THERAPY FOR ARTHRITIS WITH TRANILAST | NUON THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
| US-6127392-A | A MUSCLE RELAXANT FOR TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION; INOTROPIC AGENT | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-6046239-A | USED IN THE TREATMENT OF DISORDERS ASSOCIATED WITH SMOOTH MUSCLE CONTRACTION, VIA POTASSIUM CHANNEL AND CHLORIDE CHANNEL MODULATION SUCH AS URINARY INCONTINENCE, ASTHMA, ANGINA, PREMATURE LABOR, CONGESTIVE HEART FAILURE | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103204-A1 | Method of modulating cellular activity and agents useful for same | NLN, GAP43, CYBB | TRPA1 2236/4885MEN1 3828/4885KMT2A 3579/4885 |
| US-20110054034-A1 | METHODS OF USING CARBOXYLIC AMIDES AS ANTIMICROBIAL AGENTS | NAAA, ELANE, APEH | TRPA1 1639/4885MEN1 3484/4885KMT2A 1670/4885 |
| US-20140072584-A1 | NOVEL PHARMACEUTICAL USE OF BENZOIC ACID DERIVATIVES | NFATC1, GABRA5, GABRA6 | TRPA1 353/4885MEN1 4643/4885KMT2A 2566/4885 |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | TRPA1 4750/4885MEN1 896/4885KMT2A 490/4885 |
| US-20100160351-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERURICEMIA AND RELATED DISORDERS | XDH, SLC10A1, SLC10A6 | TRPA1 4098/4885MEN1 1944/4885KMT2A 3365/4885 |
| US-20080009519-A1 | METHOD OF MODULATING T CELL FUNCTIONING | IFNG, CD4, IDO1 | TRPA1 901/4885MEN1 3959/4885KMT2A 1759/4885 |
| US-20090197957-A1 | Methods and compositions for the treatment of pain | OPRL1, OPRK1, ACHE | TRPA1 72/4885MEN1 3723/4885KMT2A 1934/4885 |
| US-20090042987-A1 | TREATMENT OF NEUROPATHIC PAIN | OPRL1, GAP43, AANAT | TRPA1 15/4885MEN1 3473/4885KMT2A 1821/4885 |
| US-20100041756-A1 | METHOD OF MODULATING B CELL FUNCTIONING | KYNU, IDO1, IDO2 | TRPA1 1754/4885MEN1 3204/4885KMT2A 1427/4885 |
| US-20090312422-A1 | METHOD OF MODULATING CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME | NLN, GAP43, CYBB | TRPA1 2236/4885MEN1 3828/4885KMT2A 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.